公司資料
IGC Pharma, Inc. 股價、新聞與催化劑
- 股票代碼:
- IGC
- 交易所:
- NYSE
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.27 USD (+0.41%)
收盤價
最後更新: 2026年10月1日
29M USD
市值
股價為何變動
截至 2026年10月1日，IGC 上漲 0.41%，收於 $0.2700。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Alzheimer's Disease Drug Developer
IGC Pharma develops therapies and digital tools for Alzheimer's disease and related neuropsychiatric symptoms. Its portfolio includes a clinical-stage treatment for agitation and earlier disease-modifying research.
IGC-AD1 for Agitation
IGC-AD1 is an oral formulation being evaluated for agitation in patients with Alzheimer's disease. The Phase 2 CALMA program is intended to assess whether the candidate can reduce behavioral symptoms while maintaining an acceptable safety profile.
TGR-63 Disease-Modifying Research
TGR-63 is a preclinical small molecule being studied for its ability to interfere with amyloid-related processes and protect neurons. The program represents the company's longer-term effort to address underlying disease biology.
Cannabinoid and Small-Molecule Expertise
IGC's research incorporates cannabinoid pharmacology and other small-molecule approaches. The company uses formulation, preclinical, and clinical-development capabilities to advance candidates for central nervous system disorders.
AI and Biomarker Platforms
The MINT-AD and AHA initiatives apply artificial intelligence to Alzheimer's diagnosis, clinical-trial analysis, and drug development. These tools are intended to complement the therapeutic pipeline with digital and biomarker capabilities.
未來催化劑
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。